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Background: The induction of heat shock protein (HSP) 72 by mild electrical stimulation with heat shock
(MES + HS), which improves visceral adiposity and insulin resistance in mice, may be beneﬁcial in treating
metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM).
Methods: Using open-label crossover trials, 40 subjects with MS or T2DM were randomly assigned using
computer-generated random numbers to 12 weeks of therapeutic MES + HS followed by 12 weeks of no
treatment, or vice versa. During the intervention period, physical and biochemical markers were measured.
Findings: Compared to no treatment, MES + HS treatment was associated with a signiﬁcant decrease in vis-
ceral adiposity (−7.54 cm2 (−8.61%), 95% CI−8.55 to−6.53 (p = 0.037) in MS,−19.73 cm2 (−10.89%),
95% CI−20.97 to−18.49 (p = 0.003) in T2DM). Fasting plasma glucose levels were decreased by 3.74 mg/dL
(−5.28%: 95% CI −4.37 to −3.09 mg/dL, p = 0.029) in MS and by 14.97 mg/dL (10.40%: 95% CI −15.79 to
14.15 mg/dL, p b 0.001) in T2DM, and insulin levels were also reduced by 10.39% and 25.93%, respectively.
HbA1c levels showed a trend toward reduction (−0.06%) in MS, and was signiﬁcantly declined by −0.43%
(95% CI −0.55 to −0.31%, p = 0.009) in T2DM. HbA1c level of less than 7.0% was achieved in 52.5% of the
MES + HS-treated T2DM patients in contrast to 15% of the non-treated period. Several insulin resistance indices,
inﬂammatory cytokines or adipokines, including C-reactive protein, adiponectin, and tumor necrosis factor-α,
were all improved in both groups. In isolated monocytes, HSP72 expression was increased and cytokine expres-
sion was reduced following MES + HS treatment. Glucose excursions on meal tolerance test were lower after
using MES + HS in T2DM.
Interpretation: This combination therapy has beneﬁcial impacts on body composition, metabolic abnormalities,
and inﬂammation in subjects withMS or T2DM. Activation of the heat shock response byMES+HSmay provide
a novel approach for the treatment of lifestyle-related diseases.
Funding: Funding for this research was provided by MEXT KAKENHI (Grants-in-Aid for Scientiﬁc Research from
Ministry of Education, Culture, Sports, Science and Technology, Japan).© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Although DCCT, UKPDS and our Kumamoto Study (Shichiri et al.,
2000) have shown that strict glycemic control could prevent microvas-
cular complications, the increase of diabetes is still an important issue
worldwide. The increase of type 2 diabetes mellitus (T2DM) isedicine, Faculty of Life Sciences,
oto 860-8556, Japan.
ki).
and share ﬁrst authorship.
. This is an open access article underassociated with excess visceral adiposity, which is tightly linked tomet-
abolic syndrome (MS). MS is recognized as a cluster of cardiovascular
risk factors such as hyperglycemia, dyslipidemia, elevated blood pres-
sure and chronic inﬂammation (Alberti et al., 2005). Visceral fat has
been demonstrated to express more pro-inﬂammatory cytokines than
subcutaneous fat in obese states (Ohman et al., 2009). Inﬂammatory
markers such as C-reactive protein (CRP) (Tamakoshi et al., 2003) and
tumor necrosis factor (TNF)-α have been linked to MS.
Currently, there are nomedications ormodalities to reduce both vis-
ceral adiposity as well as chronic inﬂammation inMS or T2DM subjects.
Recently, we (Morino et al., 2008a; Adachi et al., 2010) and othersthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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metabolic advantages of heat shock response (HSR) activation, which
appears tomainly involve heat shockprotein (HSP) 72. HSP72 induction
by mild electrical stimulation (MES) with heat shock (HS) (Morino
et al., 2008a; Kondo et al., 2012), a transgenic system (Chung et al.,
2008), heat treatment (Gupte et al., 2009; Kavanagh et al., 2011) or
chemical inducers (Adachi et al., 2010) ameliorated abnormalmetabolic
features in animalmodels of T2DM, such as insulin resistance, hypergly-
cemia and visceral fat accumulation. Mild electrical stimulation en-
hances heat induction of HSP72 (Morino et al., 2008b) and may
directly activate insulin signaling bymodulating the insulin receptor lo-
calization of membrane components (Yano et al., 2010; Morino-Koga
et al., 2013). In this study, we investigated the effects of MES + HS on
glucose homeostasis, insulin resistance, visceral adiposity and inﬂam-
matory cytokine levels in male subjects with MS or T2DM. In addition,
inﬂammatory characteristics of circulating monocytes were examined.
This novel combination therapy may provide an additional treatment
strategy to improve metabolic abnormalities in lifestyle-related
diseases.
2. Materials and Methods
2.1. Study Participants
A total of 40 Japanese males with MS or T2DM were recruited. MS
was deﬁned by the Examination Committee for Criteria of Metabolic
Syndrome and was diagnosed on the basis of the criteria of the
American Diabetes Association. The study protocol conformed to the
ethical guidelines of the Declaration of Helsinki, and written informed
consent was obtained from each subject. These researches were ap-
proved by the Ethics Review Committee at Kumamoto University (Ad-
vanced Ethics No. 736 and Ethics No. 514). These clinical trials were
registered with an approved ICMJE clinical trial registry, UMIN (ID:
UMIN 000001149, 000003210 and 000007792). Protocol details can
be found in the Supplemental materials.
2.2. MES + HS Treatment
The devices (BioMetronome®) for producing MES + HS were pro-
vided by Tsuchiya Rubber Co. Ltd. (Kumamoto, Japan). The description
of the MES + HS device has been provided previously (Kondo et al.,
2010). Brieﬂy, MES + HS produces electrical stimulation of 1.4 ±
0.1 V/cm: the pads were positioned on the front and back of the abdo-
men, 55 pulses per second, 0.1 millisecond duration with 42 °C heat.
The padded area was 15 cm in length × 25 cm in width.
2.3. Randomization and Masking
Forty eligible MS or T2DM subjects were randomly assigned using
computer-generated random numbers into two groups by Latin square
method, each containing 20 subjects. Neither subjects nor investigators
were masked to treatment allocation at the time of enrollment.
2.4. Study Design and Clinical Protocol
This study was a prospective, randomized, open-label, crossover
trial. Forty eligible MS or T2DM subjects were randomly assigned into
two groups, each containing 20 subjects. Group I underwent a 12-
week intervention period of MES + HS followed by 12 weeks with no
treatment. The order was reversed in group II. During the MES + HS-
treatment period, subjects were instructed to use MES + HS 4 times a
week for 60 min per session. Exercise and diet alterations were
prohibited during the entire period. At 0, 12 and 24 weeks, body com-
positions, abdominal adiposity, metabolic and biochemical examination
with a 75 g oral glucose tolerance test (OGTT) in MS or a 592 kcal meal
tolerance test (MTT) in T2DMwere performed. The primary endpoint isthe amount of visceral adiposity and glucose control. Other outcomes
include blood pressure, insulin resistance, inﬂammatory cytokine levels
and the HbA1c achievement ratio of less than 7.0%. For the primary out-
come, we estimated the need to enroll 36 subjects to detect changes in
visceral fat area of 15% with MES + HS as compared to no treatment,
with statistical power of 80%, allowing for a type I (α) error of 0.05.
Allowing for a loss to follow-up rate of 10%, 40 subjects were required
to undergo randomization.
2.5. Quantiﬁcation of Adiposity
Visceral fat area (VFA) and subcutaneous fat area (SFA) at the umbil-
ical level were measured using CT scans (HiSpeed NX/i, GE Healthcare
Japan Co., Ltd., Tokyo, Japan).
2.6. Insulin Sensitivity Indices
Several indices were calculated based on the results of OGTT in MS.
The quantitative insulin-sensitivity check index (QUICKI), homeostasis
model assessment of insulin resistance (HOMA-IR), HOMA-β, compos-
ite whole body insulin sensitivity index (cWBISI) and insulinogenic
index (I.I.) were determined, as described previously (Yamashiro
et al., 2010).
2.7. Monocytes Isolation and Analysis
To investigate the characteristics of monocyte in MS or T2DM sub-
jects, 10 subjects were randomly selected. Before and after 4 weeks of
MES + HS treatment, blood samples were collected during a fasted
state. First, peripheral blood mononuclear cells (PBMCs) were isolated
using BD Vacutainer™ CPT™ (BD, Franklin Lakes, NJ). Monocytes were
subsequently isolated from the PBMCs magnetically by depletion
technique (Miltenyl Biotech. Auburn. CA). For some experiments,
monocyteswere examined before and after activationwith lipopolysac-
charide (LPS: 160 ng/mL) overnight.
2.8. mRNA Expression Determined by qRT-PCR
Real time qRT-PCRwas performed usingmRNA from isolatedmono-
cytes stimulated with LPS. The protocol of qRT-PCR has been described
previously (Adachi et al., 2010).
2.9. Statistical Analysis
Statistical analysis was performedwith SPSS software (IBM, Chicago, IL,
USA). All values were expressed as mean ± standard deviation (S.D.). The
treatment effects of MES + HS were analyzed by paired a t-test if data
were normally distributed or aWilcoxon signed-rank test if not. Sequential
changeswere analyzed by repeated-measures ANOVA. Two-sided p-values
of less than 0.05 were considered to indicate statistical signiﬁcance.
3. Results
3.1. Characteristics of MS or T2DM Subjects
Japanese males diagnosed with MS or T2DM were randomly
assigned to either group I or group II. Thereafter, subjects were random-
ized to one of two possible group sequences to receive no treatment or
MES+HS treatment (Fig. 1). The baseline values were similar between
the two groups (n= 40) (Table 1).
3.2. Adverse Effects
Therewere no harmful or adverse events including hypoglycemia or
biochemical abnormalities during these studies. As only mild electrical
Screened MS subjects (n= 41) Screened T2DM subjects (n= 43) 
Not meeting inclusion criteria (n= 3) Not meeting inclusion criteria (n= 0) 
Eligible subjects (n= 41) Eligible subjects (n= 40) 
Declined participation (n= 1) Declined participation (n= 0) 
Randomized (n= 40) Randomized (n= 40) 
MES+HS (+)  (n= 20) MES+HS (-)  (n= 20) MES+HS (+)  (n= 20) MES+HS (-)  (n= 20) 
Washout 
MES+HS (-)  (n= 20) MES+HS (+)  (n= 20) MES+HS (-)  (n= 20) MES+HS (+)  (n= 20) 
Trial completion (n= 40) Trial completion (n= 40) 
Subjects included in analysis (n= 40) Subjects included in analysis (n= 40) 
Fig. 1. Flowchart of study subjects.
82 T. Kondo et al. / EBioMedicine 1 (2014) 80–89currentwas used, no perceptiblemuscle contraction ormuscle painwas
generated in the subjects.
3.3. Adipose Tissue Composition and Physical Status
Visceral and subcutaneous adipositywere analyzed using abdominal
CT scans. After MES + HS treatment, visceral fat area (VFA) in MS
and T2DM was signiﬁcantly decreased by 12.69 ± 3.25 cm2 (−8.61%,
p = 0.037, Table 2) and 20.88 ± 4.00 cm2 (−10.89%, p = 0.003.
Table 2), respectively. Although there was no change in subcutaneous
fat area (SFA) as a result of MES + HS treatment, total abdominal adi-
posity was signiﬁcantly reduced (Table 2).
Waist circumference (Wc) also showed similar changes associated
with MES + HS treatment (Table 2). Although there was no signiﬁcant
change in MS, body mass index (BMI) was signiﬁcantly decreased by
1.42% (p = 0.027) in T2DM. Systolic or diastolic blood pressure (SBP
or DBP) was signiﬁcantly reduced both in MS and T2DM (Table 3).
3.4. Glucose Homeostasis and Insulin Resistance
Fasting plasma glucose (FPG) was signiﬁcantly decreased
(−5.95 mg/dL in MS, −15.45 mg/dL in T2DM, Table 2). Fasting
immuno-reactive insulin (IRI) showed similar alterations (−1.08 μIU/mL
in MS, −3.89 μIU/mL in T2DM, Table 2). As these FPG and IRI were
both reduced, HOMA-IR was signiﬁcantly decreased (Table 2). QUICKIshowed a trend of reduction by 2.70% (p = 0.09), and cWBISI was
signiﬁcantly increased (+20.61%, p = 0.029) in MS subjects. Upon
75 g-OGTT, FPG and glucose levels at 90 min were signiﬁcantly lower
than those at the non-treatment period (Fig. 2A). The insulin secreting
indices, I.I. and HOMA-β were also evaluated. Although IRI response
against glucose load was quite similar to the non-treatment period, I.I.
showed a signiﬁcant decrease in MS subjects (Table 2 and Fig. 2B).
HOMA-βwas unchanged during the study.
HbA1c (NGSP) levels showed a trend toward reduction (−0.07 ±
0.04%, p = 0.143) in MS, and this was signiﬁcantly decreased
(−0.49± 0.06%) from baseline in T2DM. Compared with no treatment
period, HbA1c showed a signiﬁcant reduction by0.43% (p= 0.009). The
glucose levels at 0, 120 and 300min on meal tolerance test were signif-
icantly lower (0 min; 115.5 vs 108.7 mg/dL, p = 0.039. 120 min; 251.2
vs 225.4 mg/dL, p = 0.048. 300 min; 171.8 vs 130.1 mg/dL, p = 0.041.
Fig. 2C) in T2DM. The proportion of patients who achieved the HbA1c
goal of less than 7.0% was 52.5% in theMES+HS-treated period in con-
trast to 15.0% in the untreated period (Fig. 2D). Higher pre-HbA1c indi-
cated greater reductions upon MES + HS treatment (HbA1c 5.9–6.4%:
−0.15%, 6.5–7.5%:−0.42%, 7.6–10.0%:−0.72%. Fig. 2E)
3.5. Inﬂammatory Cytokines and Adipokines
Visceral adiposity inﬂuences the production of inﬂammatory cyto-
kines and adipokines. High sensitivity CRP signiﬁcantly decreased by
Table 1
The subjects’ pre-clinical and biological characteristics.
Background characteristics of the subjects Metabolic syndrome Type 2 diabetes mellitus
Group I Group II p value Group I Group II p value
Male/females 20/0 20/0 20/0 20/0
Age (years) 53.5 ± 1.5 51.3 ± 1.6 0.332 64.6 ± 2.6 71.9 ± 2.6 0.095
Body mass index (kg/m2) 26.1 ± 0.5 27.6 ± 0.7 0.093 28.4 ± 0.9 27.4 ± 1.3 0.486
% body fat 26.7 ± 0.9 26.4 ± 0.6 0.890 – – –
Waist circumference (cm) 92.8 ± l.l 95.6 ± 1.5 0.120 98.0 ± 2.4 97.7 ± 3.2 0.867
Vsiceral fat area (cm2) 147.1 ± 6.8 149.8 ± 10.9 0.774 189.0 ± 11.8 184.4 ± 16.1 0.774
Subcutaneous fat area (cm2) 183.5 ± 13.1 200.4 ± 13.1 0.838 152.7 ± 9.2 169.3 ± 20.1 0.521
Systolic blood pressure (mm Hg) 136.8 ± 3.3 133.9 ± 2.6 0.386 138.6 ± 3.4 148.1 ± 5.4 0.205
Diastolic blood pressure (mm Hg) 86.6 ± 2.4 84.8 ± 2.3 0.588 75.2 ± 2.3 74.6 ± 2.8 0.814
Heart rate (beats/min) 69.2 ± 2.1 68.7 ± 1.6 0.862 66.7 ± 2.4 70.4 ± 2.3 0.682
Current smoking (yes/no) 7/13 8/12 N.S. 6/13 4/12 N.S.
Fasting plasma glucose (mg/dL) 107.7 ± 2.7 104.7 ± 2.9 0.457 158.5 ± 9.2 137.7 ± 10.6 0.153
Fasting insulin (mIU/mL) 10.0 ± 0.9 12.9 ± 1.6 0.141 14.5 ± 2.8 14.5 ± 3.3 0.933
HOMA-IR 2.61 ± 0.2 3.36 ± 0.5 0.146 6.03 ± 1.4 5.06 ± 1.3 0.556
QUICKI 0.34 ± 0.01 0.33 ± 0.01 0.195 0.32 ± 0.01 0.33 ± 0.01 0.394
composite WBISI 3.46 ± 0.2 3.04 ± 0.2 0.253 – – –
Insulinogenic index 1.02 ± 0.2 1.15 ± 0.2 0.670 – – –
HOMA-β 92.9 ± 12.3 1 16.5 ± 14.4 0.231 57.5 ± 11.2 90.6 ± 19.3 0.198
Blood glucose AUC on OGTT (0–2 h) (mg h/dL) 270.3 ± 8.7 274.2 ± 11.6 0.788 – – –
Insulin AUC on OGTT (0–2 h) (μIU h/mL) 138.3 ± 14.1 165.4 ± 14.6 0.203 – – –
HbAlc (%) 5.69 ± 0.11 5.59 ± 0.14 0.578 7.32 ± 0.17 7.40 ± 0.29 0.861
LDL-cholesterol (mg/dL) 138.0 ± 5.0 124.5 ± 6.9 0.125 121.3 ± 7.1 121.0 ± 8.0 0.814
HDL-cholesterol (mg/dL) 51.6 ± 1.8 48.7 ± 1.8 0.283 50.0 ± 2.6 52.0 ± 4.4 0.811
Triglyceride (mg/dL) 182.1 ± 2.1 163.4 ± 12.1 0.477 145.3 ± 19.8 173.0 ± 11.3 0.228
WBC (/μL) 6009.1 ± 317.9 6026.3 ± 343.7 0.972 54,625 ± 432.3 6643.8 ± 392.0 0.071
RBC (104/μL) 485.7 ± 7.9 502.3 ± 8.0 0.159 482.3 ± 11.8 421.1 ± 14.0 0.334
Hb (g/dL) 15.2 ± 1.2 15.7 ± 0.2 0.116 15.0 ± 0.4 13.9 ± 0.4 0.060
Plt (104/μL) 24.1 ± 0.9 22.6 ± 0.7 0.087 22.4 ± 1.2 21.5 ± 0.6 0.963
BUN (mg/dL) 13.9 ± 0.7 13.0 ± 0.7 0.376 27.5 ± 1.5 26.1 ± 3.1 0.234
Creatinine (mg/dL) 0.78 ± 0.02 0.82 ± 0.03 0.312 1.15 ± 0.12 1.36 ± 0.19 0.130
AST (IU/L) 20.8 ± 0.8 24.9 ± 2.5 0.117 32.2 ± 3.6 24.4 ± 4.3 0.175
ALT (IU/L) 25.3 ± 1.8 35.4 ± 3.7 0.089 35.7 ± 4.5 23.1 ± 4.8 0.085
LDH (IU/L) l49.0 ± 4.9 163.8 ± 4.5 0.198 228.5 ± 7.7 209.4 ± 9.4 0.113
Adiponectin (μg/mL) 3.15 ± 0.32 2.36 ± 0.34 0.094 3.36 ± 0.93 5.86 ± 1.10 0.345
Leptin (ng/mL) 5.51 ± 0.92 5.77 ± 0.58 0.813 8.38 ± 1.07 9.69 ± 1.31 0.562
Interleukin-6 (pg/mL) 1.48 ± 0.26 1.40 ± 0.1 1 0.761 2.48 ± 0.46 3.50 ± 0.72 0.309
Tumor necrosis factor-α (pg/mL) 1.64 ± 0.21 1.23 ± 0.19 0.278 1.71 ± 0.50 2.32 ± 0.39 0.386
High sensitivity C-reactive protein (ng/mL) 907.14 ± 259.9 607.9 ± 107.1 0.331 1787.7 ± 456.5 2136.9 ± 346.5 0.265
Cystatin C (mg/L) – – – 1.12 ± 0.09 1.65 ± 0.16 0.443
U-albumin creatinine ratio (mg/g·Cre) – – – 329.6 ± 252.5 152.8 ± 64.8 0.307
The subjects' pre-clinical and biological characteristics. Values are expressed as mean ± S.D. or numbers of subjects.
HOMA-IR = the homeostasis model assessment of insulin resistance. QUICKI = quantitative insulin sensitivity check index. WBISI = whole body insulin sensitivity index. HOMA-
p = the homeostasis model assessment of p-cell function. LDL = low-density lipoprotein. HDL = high-density lipoprotein. WBC = white blood cells. RBC = red blood cells.
Hb = hemoglobin. Plt = platelets. BUN = blood urea nitrogen. AST = aspartic aminotransferase. ALT = alanine aminotransferase. LDH = lactate dehydrogenase.
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MES + HS treatment. Adiponectin increased by 8.36% and 6.63% in MS
and T2DM, respectively. Leptin tended to decrease by 8.89% in MS, and
displayed a signiﬁcant reduction by 10.61% in T2DM. TNF-α dropped by
8.97% and 21.60% in MS and T2DM, respectively. Interleukin-6 showed
a signiﬁcant reduction in MS (−28.33%), but not in T2DM (−2.50%).
3.6. Other Metabolic Beneﬁts
To evaluate liver fat accumulation non-invasively, the AST/ALT ratio
and liver/spleen attenuation (L/S) ratio were calculated. In parallel with
the reduction of visceral adiposity byMES+HS treatment, the AST/ALT
ratio increased with the treatment (Table 3). The L/S ratio showed a
similar alteration (Table 3).
LDL-cholesterolwas decreased as shown in Table 3. HDL-Cwas increased
only in T2DM subjects (Table 3). Although BUNwas not changed, serum cre-
atinine (Cre)was slightly but signiﬁcantly decreased in T2DM.Urinary excre-
tion of albumin adjusted by urinary Cre was also reduced in T2DM.
3.7. Inﬂammatory Characteristics of Monocytes
To identify the effects of MES+ HS on the inﬂammatory milieu in vivo,
CD14 positive circulating monocytes were isolated, and levels of cytokineexpression were examined both in MS and T2DM. After 4 weeks of MES
+ HS treatment, HSP72 protein levels in monocytes were signiﬁcantly in-
creased by 34.5% compared to baseline in MS (Fig. 3A and B. p b 0.001),
and by 41.7% in T2DM (Fig. 4A and B. p b 0.001). Phosphorylation of AMP-
kinase (AMPK) was also increased by 79.9% in MS (Fig. 3A and B. p =
0.0002), and by 63.2% in T2DM (Fig. 4A and B. p = 0.017). Phospho-c-jun
N-terminal kinase (p-JNK) was attenuated by 42.1% in 56 KDa (p b 0.001)
and by 52.6% in 45 KDa (p b 0.001) subunits in MS (Fig. 3A and B), and by
57.8% (p =0.0002) and by 32.3% (p = 0.048), respectively in T2DM
(Fig. 4AandB). LPS-stimulatedNF-κBp65 subunitnuclear translocation, visu-
alized by immunoﬂuorescence, was attenuated in both MS and T2DM sub-
jects after MES+ HS treatment (Figs. 3C and 4C). In MS, mRNA expression
for CRP, IL-6, NF-κB and TNF-α showed reductions by 28.0% (p = 0.006),
7.5% (p = 0.36), 22.7% (p = 0.044) and 23.3% (p = 0.030), respectively
(Fig. 3D). In T2DM,mRNA expression of CRP, IL-6, NF-κB and TNF-αwas de-
creased by 24.9% (p = 0.046), 15.1% (p = 0.06), 17.7% (p = 0.011) and
33.5% (p= 0.025), respectively (Fig. 4D).4. Discussion
Obesity due to sedentary lifestyle and/or unbalanced diet causes
lifestyle-related diseases such asMS or T2DM, characterized by elevated
blood glucose, often accompanied by dyslipidemia and hypertension
Table 2
Primary outcomes.
Metabolic syndrome
Adiposity No treatment MES + HS
Baseline No treatment Δ no treat Baseline MES + HS ΔMES + HS p value
Visceral fat area (cm2) 148.4 ± 6.4 143.2 ± 6.8 −5.2 147.4 ± 6.6 134.7 ± 6.4 −12.7 0.037
SubQ fat area (cm2) 191.7 ± 9.5 191.0 ± 9.6 −0.7 190.3 ± 9.1 187.4 ± 8.5 −2.9 0.321
Total fat area (cm2) 340.1 ± 13.2 334.3 ± 13.0 −5.9 337.7 ± 12.7 322.1 ± 12.0 −15.6 0.019
BMI (kg/m2) 26.8 ± 0.5 26.7 ± 0.6 −0.04 26.8 ± 0.4 25.8 ± 0.4 −0.10 0.328
Wc (cm) 94.1 ± 1.0 93.9 ± 1.0 −0.2 93.9 ± 1.1 92.9 ± 1.1 −1.0 0.033
Glucose control
Blood glucose at 0 min (mg/dL) 112.3 ± 1.8 110.1 ± 2.4 −2.2 112.7 ± 1.8 106.7 ± 2.5 −6.0 0.029
Insulin at 0 min (μIU/mL) 11.4 ± 1.0 11.7 ± 1.0 0.3 10.4 ± 0.8 9.3 ± 0.7 − l.l 0.049
HOMA-IR 3.2 ± 0.3 3.2 ± 0.3 0.05 2.9 ± 0.2 2.5 ± 0.2 −0.4 0.024
Insulinogenic index 1.7 ± 0.4 1.4 ± 0.3 −0.3 1.7 ± 0.4 1.0 ± 0.1 −0.7 0.042
HOMA-β 87.8 ± 9.0 88.8 ± 7.3 1.0 78.7 ± 6.5 84.0 ± 6.7 5.3 0.732
QUICKI 0.33 ± 0.01 0.33 ± 0.01 −0.003 0.33 ± 0.01 0.34 ± 0.01 0.01 0.09
Composite WBISI 3.2 ± 0.2 3.5 ± 0.2 0.3 3.3 ± 0.2 4.0 ± 0.3 0.7 0.029
Glucose AUC 334.2 ± 10.6 330.4 ± 12.3 −3.8 337.2 ± 12.4 325.1 ± 12.9 −12.1 0.150
IRI AUC 152.6 ± 10.6 148.1 ± 12.2 −4.5 145.3 ± 9.6 139.4 ± 9.7 −5.9 0.385
HbAlc (%) 5.24 ± 0.09 5.23 ± 0.08 −0.01 5.29 ± 0.08 5.22 ± 0.09 −0.07 0.143
Type 2 diabetes mellitus
Adiposity No treatment MES + HS
Baseline No treatment Δ no treat Baseline MES + HS ΔMES + HS p value
Visceral fat area (cm2) 186.0 ± 9.8 187.1 ± 9.3 l.l 191.8 ± 9.5 179.9 ± 7.0 −20.9 0.003
SubO fat area (cm2) 160.4 ± 11.1 170.0 ± 12.6 9.6 167.8 ± 12.4 169.9 ± 12.5 2.1 0.041
total fat area (cm2) 346.4 ± 19.2 357.1 ± 20.7 10.7 359.6 ± 20.6 340.8 ± 17.6 −18.8 0.005
BMI (kg/m2) 27.8 ± 0.8 27.8 ± 0.8 −0.02 27.8 ± 0.8 27.4 ± 0.8 −0.4 0.027
Wc (cm) 97.7 ± 2.0 100.5 ± 3.1 2.8 97.9 ± 2.1 95.2 ± 1.8 −2.7 0.021
Glucose control
Fasting blood glucose (mg/dL) 147.7 ± 7.1 148.2 ± 6.2 0.5 148.6 ± 6.2 133.1 ± 5.4 −15.5 0.000 l
Fasting insulin (μIU/mL) 14.3 ± 2.1 13.6 ± 1.6 −0.7 15.0 ± 2.0 11.1 ± 1.6 −3.9 0.024
HOMA-IR 5.5 ± 0.9 5.1 ± 0.7 −0.4 5.7 ± 0.9 3.8 ± 0.5 −1.9 0.009
HOMA-β 73.2 ± 11.4 65.4 ± 8.4 −7.8 70.8 ± 9.4 66.8 ± 12.4 −4.0 0.362
HbAlc (%) 7.35 ± 0.17 7.29 ± 0.1 −0.06 7.27 ± 0.17 6.78 ± 0.14 −0.49 0.009
The results of MES + HS intervention data compared to no treatment period. Values are expressed as mean ± S.D. Other abbreviations are the same as Table 1.
84 T. Kondo et al. / EBioMedicine 1 (2014) 80–89with chronic inﬂammation resulting from an over-accumulation of
visceral fat (Alberti et al., 2005). In this study, we demonstrated that
MES + HS, which activates the heat shock response (Morino et al.,
2008a; Kondo et al., 2012), signiﬁcantly improved visceral adiposity, in-
sulin resistance, glucose homeostasis and cytokine levels in males with
MS or T2DM.
MES + HS treatment signiﬁcantly improved insulin resistance in
subjects withMS or T2DM. Particularly in T2DM,we have identiﬁed sig-
niﬁcant improvements in HbA1c, FPG, postprandial glucose excursion
and insulin resistance. More than half of the T2DM subjects achieved
HbA1c less than 7.0%.
Insulin resistance is a central feature of theseMS and T2DM, and im-
paired insulin signaling may be associated with attenuated HSP72 pro-
duction (Bruce et al., 2003; Kurucz et al., 2002). HSP72 is a cytoplasmic
molecular chaperone, which is induced by several stimuli such as heat
shock, viral infection or heavy metal contamination etc., and protects
cells from apoptosis or cellular dysfunction caused by such cell stresses
(Hooper et al., 2014).
HSP72 transcription is regulated by insulin signaling target, glycogen
synthase kinase (GSK)-3β.
Phosphorylation of GSK-3β blocks the GSK-3 inactivation of HSF-1
and thereby increases activity of HSF-1 (Hooper et al., 2014).
It is known that HSP72 inhibits JNK activity, resulting in the attenu-
ation of inﬂammatory signals. However, chronic activation of stress sig-
nals down-regulates HSP72 levels through insulin resistance, and
results in further activation of inﬂammatory milieu. This vicious
metabolic cycle characterized by systemic inﬂammation, impaired
insulin signaling and attenuated HSR is proposed to occur in MS and
T2DM (Hooper, 2009). These components could be improved by theactivation of HSR. Indeed, induction of HSP72 by several modalities
such as MES + HS, whole-body hyperthermia, muscle-speciﬁc HSP72
overexpression, and HSP inducers has been shown to improve insulin
signaling in mice, monkeys and humans (Morino et al., 2008a; Adachi
et al., 2010; Chung et al., 2008; Kondo et al., 2012; Kavanagh et al.,
2011; Literati-Nagy et al., 2009).
The beneﬁcial effects of HSP72 in insulin signalingmay be partly ex-
plained by the suppression of JNK (Chung et al., 2008). Deletion of JNK1
protects mice from high-fat diet-induced insulin resistance, in part
through decreased adiposity. Indeed, suppression of JNK in diabetic
mice ameliorates insulin resistance and glucose intolerance (Kaneto
et al., 2004). It has also been reported that an HSP72 polymorphism is
linked to increased obesity and diabetes risk in humans (Zouari
Bouassida et al., 2004). Induction of HSP72 enhances mitochondrial ca-
pacity and/or function (Chung et al., 2008; Henstridge et al., 2014), and
suppresses JNK activity (Morino et al., 2008a; Kondo et al., 2012). In ad-
dition, uncoupling protein-1 mRNA expression in brown adipose tissue
was increased in MES + HS-treated diabetic animals (Morino et al.,
2008a). Moreover, MES + HS treatment activates AMPK in mice
(Kondo et al., 2012). In fact, AMPKα1 knockouts showed increased vis-
ceral adiposity with insulin resistance (Zhang et al., 2012). As we have
identiﬁed the activation of AMPK in monocytes, this may contribute to
reduce visceral adiposity. In addition, testosterone treatment amelio-
rates metabolic abnormalities, including adipocyte hypertrophy,
adipose tissue dysfunction, tissue hypoxia and insulin resistance
(Maneschi et al., 2012). Heat treatment activates androgen effect espe-
cially in lipid peroxidation, indicating that activation of androgen signal
through HSR activation may also participate in the beneﬁcial effects of
MES + HS. These mechanisms may participate in the reduction of
Table 3
Secondary outcomes.
Metabolic syndrome
Inﬂammation No treatment MES + HS
Baseline No treatment Δ no treat Baseline MES + HS ΔMES + HS p value
hs-CRP (ng/mL) 767.9 ± 153.6 1516.8 ± 402.3 748.9 1549.3 ± 420.6 715.0 ± 114.0 −834.3 0.025
Adiponectin (μg/mL) 2.8 ± 0.2 2.7 ± 0.2 −0.1 2.9 ± 0.2 3.1 ± 0.2 0.2 0.020
Leptin (ng/mL) 5.6 ± 0.5 5.5 ± 0.6 −0.1 5.5 ± 0.5 5.0 ± 0.4 −0.5 0.120
TNF-α (pg/mL) 1.4 ± 0.1 1.3 ± 0.1 −0.1 1.5 ± 0.1 1.3 ± 0.1 −0.2 0.020
IL-6 (pg/mL) 1.5 ± 0.1 1.6 ± 0.2 0.1 1.8 ± 0.2 1.3 ± 0.1 −0.5 0.036
Blood pressure
Systolic blood pressure (mm Hg) 135.5 ± 2.5 134.9 ± 2.5 −0.6 135.0 ± 2.7 129.3 ± 1.8 −5.7 0.034
Diastolic blood pressure (mm Hg) 85.8 ± 1.7 86.3 ± 1.4 −0.5 85.0 ± 1.6 82.6 ± 1.3 −2.4 0.038
Heart rate (bpm) 68.9 ± 1.4 70.2 ± 1.5 1.3 69.9 ± 1.5 69.6 ± 1.4 −0.3 0.237
Others
WBC (/μL) 6015.0 ± 239.2 5990.0 ± 287.9 −25.0 6112.5 ± 254.02 5665.0 ± 256.5 −447.5 0.037
Hb (g/dL) 15.5 ± 0.2 15.6 ± 0.2 0.1 15.6 ± 0.2 15.4 ± 0.2 −0.2 0.357
Ht (%) 46.7 ± 0.5 47.7 ± 0.4 1.0 47.2 ± 0.5 47.4 ± 0.4 0.2 0.956
Plt (×104/μL) 22.8 ± 0.6 22. ± 0.6 0.1 22.4 ± 0.6 23.1 ± 0.7 0.7 0.275
AST (U/L) 22.7 ± 1.3 24.8 ± 1.3 2.1 23.3 ± 1.4 23.1 ± 1.4 −0.2 0.104
ALT (U/L) 30.5 ± 2.2 31.4 ± 2.1 0.9 30.3 ± 2.2 26.4 ± 1.7 −3.9 0.012
AST/ALT 0.80 ± 0.04 0.84 ± 0.04 0.04 0.83 ± 0.04 0.94 ± 0.05 0.11 0.023
L/S ratio 0.994 ± 0.001 0.999 ± 0.001 0.005 0.996 ± 0.002 1.092 ± 0.002 0.096 0.003
LDH (U/L) 156.0 ± 3.6 162.4 ± 3.0 6.4 156.4 ± 3.5 161.3 ± 3.5 4.9 0.310
BUN (mg/dL) 13.6 ± 0.5 14.3 ± 0.5 0.7 14.0 ± 0.5 14.2 ± 0.5 0.2 0.139
Cre (mg/dL) 0.80 ± 0.02 0.82 ± 0.02 0.02 0.81 ± 0.02 0.79 ± 0.02 −0.02 0.010
LDL-C (mg/dL) 131.6 ± 4.4 131.9 ± 4.0 0.3 133.3 ± 4.0 126.1 ± 3.8 −7.2 0.040
HDL-C (mg/dL) 50.4 ± 1.3 51.4 ± 1.5 1.0 50.4 ± 1.5 50.2 ± 1.5 −0.2 0.221
TG (mg/dL) 171.5 ± 13.0 164.4 ± 14.6 −7.1 156.1 ± 10.6 150.0 ± 11.3 −6.1 0.540
Type 2 diabetes mellitus
Inﬂammation No treatment MES + HS
Baseline No treatment Δ no treat Baseline MES + HS ΔMES + HS p value
hs-CRP (ng/mL) 3923.3 ± 1779.0 4206.5 ± 1932.1 283.2 4158.1 ± 1920.7 3969.5 ± 1882.4 −188.6 0.047
Adiponectin (μg/mL) 4.7 ± 0.6 3.8 ± 0.3 −0.9 3.9 ± 0.3 4.2 ± 0.5 0.3 0.003
Leptin (ng/mL) 8.9 ± 0.9 10.5 ± 1.1 1.6 10.2 ± 1.1 9.1 ± 0.8 −1.1 0.003
TNF-α (pg/mL) 2.0 ± 0.3 2.7 ± 0.5 0.7 2.5 ± 0.5 2.0 ± 0.3 −0.5 0.001
IL-6 (pg/mL) 3.0 ± 0.4 2.8 ± 0.4 −0.2 2.8 ± 0.4 2.9 ± 0.4 0.1 0.230
Blood pressure
Systolic blood pressure (mm Hg) 143.0 ± 3.3 142.4 ± 3.0 −0.6 136.7 ± 3.0 129.1 ± 2.5 −7.6 0.013
Diastolic blood pressure (mm Hg) 74.7 ± 1.8 73.6 ± 1.9 −1.1 71.7 ± 1.9 66.5 ± 2.0 −5.2 0.005
Heart rate (bpm) 70.1 ± 1.8 70.6 ± 1.5 0.5 69.9 ± 1.6 68.2 ± 1.8 −1.7 0.110
Others
WBC (/μL) 6030.3 ± 301.3 5975.8 ± 259.2 −54.5 6041.1 ± 250.6 6144.1 ± 250.6 103.0 0.512
Hb (g/dL) 14.5 ± 0.3 14.2 ± 0.3 −0.3 14.3 ± 0.3 14.3 ± 0.2 −0.04 0.283
Ht (%) 42.0 ± 1.0 41.3 ± 0.9 −0.7 41.7 ± 1.0 41.3 ± 0.7 −0.4 0.702
Plt (×104/μL) 19.3 ± 0.8 18.4 ± 0.7 −1.1 18.0 ± 0.7 19.8 ± 0.8 1.8 0.175
AST (U/L) 28.5 ± 2.8 27.2 ± 2.2 −1.3 29.5 ± 2.6 26.2 ± 2.1 −3.3 0.137
ALT (U/L) 29.7 ± 3.5 29.8 ± 3.0 0.1 29.8 ± 3.0 22.7 ± 1.5 −7.1 0.068
AST/ALT 1.08 ± 0.06 1.01 ± 0.05 −0.07 1.09 ± 0.06 1.19 ± 0.07 0.09 0.018
L/S ratio 0.965 ± 0.001 0.973 ± 0.001 0.008 0.973 ± 0.002 1.084 ± 0.002 0.111 0.032
LDH (U/L) 219.5 ± 6.2 204.3 ± 4.3 −15.2 213.0 ± 5.8 200.5 ± 4.2 −12.5 0.353
BUN (mg/dL) 21.6 ± 1.8 20.9 ± 1.7 −0.7 21.0 ± 1.7 19.5 ± 1.6 −1.5 0.224
Cre (mg/dL) 1.2 ± 0.1 1.2 ± 0.1 0.02 1.2 ± 0.1 1.1 ± 0.1 −0.1 0.013
LDL-C (mg/dL) 121.2 ± 5.3 121.7 ± 5.0 0.5 121.6 ± 5.1 112.4 ± 4.7 −9.2 0.007
HDL-C (mg/dL) 51.0 ± 2.5 50.3 ± 2.8 −0.7 49.9 ± 2.7 52.6 ± 2.6 2.7 0.009
TG (mg/dL) 158.4 ± 12.0 162.4 ± 10.3 4.09 ± 9.07 161.7 ± 11.6 148.0 ± 12.9 −13.7 0.109
Cystatin C (mg/L) 1.4 ± 0.1 1.4 ± 0.1 −0.005 1.4 ± 0.1 1.4 ± 0.1 0.007 0.358
U-ACR (mg/g⋅Cre) 199.4 ± 135.8 102.4 ± 54.7 −37.0 194.4 ± 136.0 89.5 ± 40.7 −104.9 0.047
The results of MES + HS intervention data compared to no treatment period. Values are expressed as mean ± S.D.
L/S ratio = Liver to spleen ratio on computed tomography.
U-ACR = Urinary albumin creatinine ratio. Other abbreviations are the same as Table 1.
85T. Kondo et al. / EBioMedicine 1 (2014) 80–89visceral adiposity by MES + HS treatment, which need further
investigation.
Increased production of pro-inﬂammatory cytokines is associated
with impaired insulin sensitivity (Tamakoshi et al., 2003).We previous-
ly reported that activation of the HSR byMES+HS in diabetic mice was
associated with metabolic beneﬁts, accompanied by improvements in
inﬂammatory cytokine productions (Morino et al., 2008a). In this
study, we observed similar cytokine changes in human subjects withMS and T2DM. Although this may be partly explained by the reduction
in visceral adiposity, we also reported signiﬁcant reductions in CRP and
TNF-α levels byMES+HS in healthy subjectswithout any body compo-
sition changes (Kondo et al., 2010). These results suggest a possible di-
rect association between HSR activation and suppression of systemic
inﬂammation. High serum CRP levels are associated with reduced
HSP72 levels (Armutcu et al., 2008), and are positively regulated by
NF-κB, which can be attenuated by HSP72. Indeed, we observed a
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86 T. Kondo et al. / EBioMedicine 1 (2014) 80–89signiﬁcant increase in HSP72 with reduction of NF-κB nuclear accumu-
lation in monocytes after MES + HS treatment. HSP72 also decreases
TNF-α levels by suppression of NF-κB as well. Therefore, induction of
HSP72 by MES + HS could decrease inﬂammatory cytokines through
suppression of NF-κB activation. It is also possible that an anti-
inﬂammatory effect ofMES+HScould be achieved byAMPKactivation,
because AMPK α1 deﬁciency in macrophages markedly increases
the pro-inﬂammatory status (Zhang et al., 2012). As chronic ac-
tivation of inﬂammatory status is associated with atherogenesis, anti-
inﬂammatory effect of MES + HSmay contribute to limit future vascu-
lar complications.
Because visceral fat produces angiotensinogen and increases sympa-
thetic nervous activity, MS and T2DM are often associated withhypertension. In this regard, reduction in blood pressure as a result of
MES+ HS treatment could be explained, at least in part, by a reduction
in visceral adiposity. Recently, it has been shown that heat treatment in
high fat-fed mice augmented angiotensin (Shichiri et al., 2000; Alberti
et al., 2005; Ohman et al., 2009; Tamakoshi et al., 2003; Morino et al.,
2008a; Adachi et al., 2010; Chung et al., 2008), which counteracts
against angiotensin II, through Mas receptor/eNOS axis that may
improve blood pressure and endothelial dysfunction (Karpe and
Tikoo, 2014). Therefore, both reductions in visceral fat and eNOS activa-
tion may contribute to ameliorate hypertension upon MES + HS
treatment.
Hepatic steatosis is considered to be one of the phenotypes of
lifestyle-related diseases. Our results indicate that activation of the HSR
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87T. Kondo et al. / EBioMedicine 1 (2014) 80–89byMES+HS improved surrogatemarkers of fatty liver. Although precise
interaction betweenHSR activation and improvement of fatty liver is still
unknown, naringin, a bioﬂavonoid isolated from grapefruit, activates
HSP72 and attenuates hepatic steatosis (Sharmaet al., 2011). Alternative-
ly, endoplasmic reticulum (ER) stress attenuation by HSR activationmay
be involved in this process, becauseHSP72 enhances ER capacity, and he-
patic lipid accumulation is correlated with ER stress (Gupta et al., 2010).The molecular mechanisms involved in metabolic beneﬁts of
MES+HS appear to be similar to those observed in exercise, particular-
ly in HSP72 induction and AMPK activation (Zhang et al., 2009). Indeed,
8 weeks of endurance training in diabetic rats increased HSP72 expres-
sion (Atalay et al., 2004). It is also proposed that HSR activators share
metabolic pathways associated with exercise with activation of AMPK
(Hooper et al., 2014).
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88 T. Kondo et al. / EBioMedicine 1 (2014) 80–89Thus, MES + HS treatment may mimic exercise training sharing
with similar mechanisms and results.4.1. Limitations
This studywas conducted in relatively small number, and the partic-
ipants were limited to male only in order to preclude menstruation
cycle, which may disturb metabolic parameters.5. Conclusion
MES+HS treatment exerts anti-visceral obesity, anti-hypertensive,
anti-diabetic and anti-inﬂammatory effects with no harmfulness, possi-
bly throughHSP72 induction andAMPK activation.Moreover, it can also
be used in physically handicapped or bed-ridden patients who are un-
able to follow an exercise regimen.MES+HS could be analogous to ex-
ercise training in terms of HSP72 induction and AMPK activation, and
might confer additional beneﬁts, such as anti-atherogenic effect. HSR
89T. Kondo et al. / EBioMedicine 1 (2014) 80–89activation by physical MES+HS systemmay be an alternative and ben-
eﬁcial therapeutic approach to the treatment of lifestyle-related
diseases.
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